에볼라 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 지역별 및 부문별 예측(2026-2033년)

Ebola Market Summary

The global Ebola market size was estimated at USD 1.20 billion in 2025 and is projected to grow from USD 1.29 billion in 2026 to USD 2.27 billion by 2033, growing at a CAGR of 8.3% from 2026 to 2033. The North America Ebola market held the largest global share of 40.9% in 2025.

The market is witnessing sustained growth due to the increasing emphasis on outbreak preparedness, preventive immunization programs, and rapid-response healthcare infrastructure across high-risk regions. Healthcare organizations are prioritizing vaccination strategies to strengthen epidemic containment efficiency and reduce mortality rates during outbreaks.

The commercial availability of approved vaccines such as Ervebo and Zabdeno/Mvabea has significantly improved large-scale deployment capabilities across Africa and other vulnerable regions. Expanding cold-chain infrastructure, improvements in emergency healthcare logistics, and rising awareness regarding viral hemorrhagic fever transmission risks are further supporting vaccine accessibility and preparedness initiatives. Healthcare providers are also increasingly focusing on rapid immunization coverage for frontline healthcare workers and vulnerable populations exposed to outbreak environments. For instance, in May 2026, the World Health Organization declared the Ebola disease outbreak in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern (PHEIC) following the rapid spread of the Bundibugyo virus strain. The organization reported 246 suspected cases and 80 suspected deaths across at least 3 health zones in Ituri Province, DRC, as of 16 May 2026. In Uganda, 2 confirmed cases linked to travel from DRC were identified, while 8 out of 13 collected samples tested positive for the Bundibugyo virus. The outbreak also resulted in 4 deaths among healthcare workers, highlighting the urgent need for expanded vaccination coverage, outbreak preparedness, and infection control programs across affected regions.

Global Ebola Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Ebola market report based on type and region:

• Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Therapeutic
  • Product Type
• Vaccine
  • ERVEBO
  • Zabdeno/Mvabea
• Monoclonal Antibodies
  • Inmazeb
  • Ebanga
• Supportive Care Therapies
  • Route of Administration
• Intravenous (IV)
• Intramuscular (IM)
• Other
  • Procurement Channel
• Public
• Private
• Diagnostic
  • Test Type
• Molecular Diagnostic Tests
  • RT-PCR Molecular Diagnostic Tests
  • Real-Time RT-PCR Assays
  • Others
• Rapid Diagnostic Tests
• Immunodiagnostic Assays
• Others
  • End Use
• Hospitals & Clinics
• Diagnostic Laboratories
• Government & Public Health Agencies
• Research Institutes
• NGOs & International Health Organizations
• Regional Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Ebola Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Ebola Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million/Billion)
• 4.4. Therapeutic
  • 4.4.1. Therapeutic Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.2. Product Type
    • 4.4.2.1. Product Type Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.2.2. Vaccine
      • 4.4.2.2.1. Vaccine Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.2.2. ERVEBO
        • 4.4.2.2.2.1. ERVEBO Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.2.3. Zabdeno/Mvabea
        • 4.4.2.2.3.1. Zabdeno/Mvabea Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.2.3. Monoclonal Antibodies
      • 4.4.2.3.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.3.2. Inmazeb
        • 4.4.2.3.2.1. Inmazeb Market, 2021 - 2033 (USD Million/Billion)
      • 4.4.2.3.3. Ebanga
        • 4.4.2.3.3.1. Ebanga Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.2.4. Supportive Care Therapies
      • 4.4.2.4.1. Supportive Care Therapies Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.3. Route of Administration
    • 4.4.3.1. Route of Administration Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.3.2. Intravenous (IV)
      • 4.4.3.2.1. Intravenous (IV) Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.3.3. Intramuscular (IM)
      • 4.4.3.3.1. Intramuscular (IM) Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.3.4. Other
      • 4.4.3.4.1. Other Market, 2021 - 2033 (USD Million/Billion)
  • 4.4.4. Procurement Channel
    • 4.4.4.1. Procurement Channel Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.4.2. Public
      • 4.4.4.2.1. Public Market, 2021 - 2033 (USD Million/Billion)
    • 4.4.4.3. Private
      • 4.4.4.3.1. Private Market, 2021 - 2033 (USD Million/Billion)
• 4.5. Diagnostic
  • 4.5.1. Diagnostic Market, 2021 - 2033 (USD Million/Billion)
  • 4.5.2. Test Type
    • 4.5.2.1. Test Type Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.2.2. Molecular Diagnostic Tests
      • 4.5.2.2.1. Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.2.2. RT-PCR Molecular Diagnostic Tests
        • 4.5.2.2.2.1. RT-PCR Molecular Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.2.3. Real-Time RT-PCR Assays
        • 4.5.2.2.3.1. Real-Time RT-PCR Assays Market, 2021 - 2033 (USD Million/Billion)
      • 4.5.2.2.4. Others
        • 4.5.2.2.4.1. Others Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.2.3. Rapid Diagnostic Tests
      • 4.5.2.3.1. Rapid Diagnostic Tests Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.2.4. Immunodiagnostic Assays
      • 4.5.2.4.1. Immunodiagnostic Assays Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.2.5. Others
      • 4.5.2.5.1. Others Market, 2021 - 2033 (USD Million/Billion)
  • 4.5.3. End Use
    • 4.5.3.1. End Use Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3.2. Hospitals & Clinics
      • 4.5.3.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3.3. Diagnostic Laboratories
      • 4.5.3.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3.4. Government & Public Health Agencies
      • 4.5.3.4.1. Government & Public Health Agencies Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3.5. Research Institutes
      • 4.5.3.5.1. Research Institutes Market, 2021 - 2033 (USD Million/Billion)
    • 4.5.3.6. NGOs & International Health Organizations
      • 4.5.3.6.1. NGOs & International Health Organizations Market, 2021 - 2033 (USD Million/Billion)

Chapter 5. Ebola Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2025 & 2033
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 5.4. North America
  • 5.4.1. North America Ebola Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million/Billion)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Target Disease Prevalence
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. Reimbursement Framework
    • 5.4.2.5. U.S. Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Target Disease Prevalence
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Reimbursement Framework
    • 5.4.3.5. Canada Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Target Disease Prevalence
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. Reimbursement Framework
    • 5.4.4.5. Mexico Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.5. Europe
  • 5.5.1. Europe Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Target Disease Prevalence
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement Framework
    • 5.5.2.5. UK Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Target Disease Prevalence
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement Framework
    • 5.5.3.5. Germany Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Target Disease Prevalence
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. Reimbursement Framework
    • 5.5.4.5. France Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Target Disease Prevalence
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Reimbursement Framework
    • 5.5.5.5. Italy Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Target Disease Prevalence
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Reimbursement Framework
    • 5.5.6.5. Spain Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.7. Denmark
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Target Disease Prevalence
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. Reimbursement Framework
    • 5.5.7.5. Denmark Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.8. Sweden
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Target Disease Prevalence
    • 5.5.8.3. Regulatory Framework
    • 5.5.8.4. Reimbursement Framework
    • 5.5.8.5. Sweden Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.5.9. Norway
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Target Disease Prevalence
    • 5.5.9.3. Regulatory Framework
    • 5.5.9.4. Reimbursement Framework
    • 5.5.9.5. Norway Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Target Disease Prevalence
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement Framework
    • 5.6.2.5. Japan Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Target Disease Prevalence
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement Framework
    • 5.6.3.5. China Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Target Disease Prevalence
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement Framework
    • 5.6.4.5. India Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Target Disease Prevalence
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement Framework
    • 5.6.5.5. Australia Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.6. South Korea
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Target Disease Prevalence
    • 5.6.6.3. Regulatory Framework
    • 5.6.6.4. Reimbursement Framework
    • 5.6.6.5. South Korea Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Target Disease Prevalence
    • 5.6.7.3. Regulatory Framework
    • 5.6.7.4. Reimbursement Framework
    • 5.6.7.5. Thailand Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.7. Latin America
  • 5.7.1. Latin America Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Target Disease Prevalence
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. Reimbursement Framework
    • 5.7.2.5. Brazil Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Target Disease Prevalence
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Reimbursement Framework
    • 5.7.3.5. Argentina Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.8. Middle East and Africa
  • 5.8.1. Middle East and Africa Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Target Disease Prevalence
    • 5.8.2.3. Regulatory Framework
    • 5.8.2.4. Reimbursement Framework
    • 5.8.2.5. South Africa Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Target Disease Prevalence
    • 5.8.3.3. Regulatory Framework
    • 5.8.3.4. Reimbursement Framework
    • 5.8.3.5. Saudi Arabia Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Target Disease Prevalence
    • 5.8.4.3. Regulatory Framework
    • 5.8.4.4. Reimbursement Framework
    • 5.8.4.5. UAE Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Target Disease Prevalence
    • 5.8.5.3. Regulatory Framework
    • 5.8.5.4. Reimbursement Framework
    • 5.8.5.5. Kuwait Ebola Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Merck & Co.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Johnson & Johnson
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Regeneron Pharmaceuticals
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Ridgeback Biotherapeutics
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. Cepheid
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. altona Diagnostics
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. OraSure Technologies
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. BioFire Diagnostics
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Bavarian Nordic
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Gilead Sciences
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives